CRISPR gene editing offers new hope for treating Duchenne
CRISPR shows promise in correcting DMD mutations and restoring dystrophin, and future patients may benefit from personalized strategies.
CRISPR shows promise in correcting DMD mutations and restoring dystrophin, and future patients may benefit from personalized strategies.
For people with DMD, physical activity is about more than walking, with independence and quality of life tied to meaningful movement.
Muscle weakness in Duchenne muscular dystrophy (DMD) does not follow a simple decline, but has periods of stability before worsening.
Researchers identified two previously unreported mutations in the Dystrophin gene, providing new insights into muscular dystrophy.
Patients of different racial and ethnic backgrounds with DMD received different treatments and had varying health care costs.
Many individuals with DMD/BMD need assistance with daily living and employment as they transition into adulthood.